[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356148-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356148-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tumor-mutational-landscape-and-its-correlation-with-histopathological-characteristics-in-breast-cancer","Tumor Mutational Landscape and Its Correlation With Histopathological Characteristics in Breast Cancer","","Breast cancer associations between clinicopathologic characteristics, genetic changes, and subtype-specific molecular patterns are increasingly detailed. This study evaluates how pathological and clinical variables influence the actionability of Next Generation Sequencing (NGS)-based tumor molecular data. Data from 227 patients link pathology records to HER2, ER, PR, Ki67, grade, metastatic site, age, and a 1021-gene NGS panel with TMB and MSI.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tumor-mutational-landscape-and-its-correlation-with-histopathological-characteristics-in-breast-cancer/356148/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tumor-mutational-landscape-and-its-correlation-with-histopathological-characteristics-in-breast-cancer/356148.png","ImageObject",300,407,{"name":42,"@type":43},"hdkawk","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How many breast cancer patients were included in the study, and what molecular platform was used?","Question",{"text":63,"@type":64},"The study included 227 breast cancer patients. A 1021-gene NGS-based multigene panel was used, together with tumor mutational burden (TMB) and microsatellite instability (MSI).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which breast cancer subtypes showed distinct genomic alteration patterns?",{"text":68,"@type":64},"HR+/HER2- tumors were enriched for PIK3CA and ESR1 alterations, while triple-negative breast cancer (TNBC) was dominated by TP53 alterations.",{"name":70,"@type":61,"acceptedAnswer":71},"What factors were associated with higher clinically actionable alterations?",{"text":72,"@type":64},"Actionable alterations were more frequent in HR+/HER2-tumors and increased on-label actionability up to 64.5% when tumor-agnostic biomarkers (TMB/MSI) were included. The presence of actionable alterations was significantly higher in metastatic tumors, and age was reported as the only independent predictor.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356148,1790211985,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":30,"preview_urls":147},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","doi: 10.21873/cgp.20616  \nTumor Mutational Landscape and Its Correlation With Histopathological Characteristics in Breast Cancer  \nEIRINI PAPADOPOULOU1, MAROULIO STATHOULOPOULOU2, MARIA MATIATOU2, PANAGIOTIS KARATHANASIS2, XENOFON XENAKIS3, GRIGORIOS PESMATZOGLOU4, IOANNIS FYSSAS5, KONSTANTINOS LOUIS6, DIMITRIOS MANIATIS7, ANASTASIA EKMEKTZOGLOU8, DIMITRIOS ALEXANDROU9, CHRISTOS KALIVOPOULOS10, CHRISTOS KANISTRAS11, NIKOLAOS KATSIAKIS12, IOANNA KONSTANTIADOU13, CHRISTOS KAVAZIS8, ATHANASIOS KOKOLAKIS8,  \nNIKOLAOS PAPAIOANNOU14, ANNASACHOULIDOU15, ELEFTHERIOS SFAKIANAKIS16, SOFIA TRIANTAFYLLIDOU17, SOFIA FILIPPIDOU18, CHRISTOS DAMASKOS19, GEORGE LAZARIDIS20, FILIPPOS KOINIS21, EIRINI BIZIOTA22, ANGELOS KOUTRAS23, AIKATERINI KOTSORI24 and VASSILEIOS VENIZELOS2  \n1Genekor Medical S.A., Athens, Greece;  \n2 ΕUSOMA-Certified Multidisciplinary Breast Center, Metropolitan Hospital, Piraeus, Greece;  \n3 Henry Dunant Hospital, Athens, Greece; 4 Eugenideio Hospital, Athens, Greece;  \n5 Prolipsis Medical Diagnostic Center, Athens, Greece;  \n6Third Department of Obstetrics and Gynecology, University General Hospital “ATTIKON”, Medical School, National and Kapodistrian University of Athens, Athens, Greece;  \n7Second Breast Clinic, General Maternity and Gynecology Clinic, IASO General Hospital, Athens, Greece;  \n8 Interbalkan Medical Center, Thessaloniki, Greece; 9 Papageorgiou General Hospital, Thessaloniki, Greece;  \n10Agios Savvas Anticancer Hospital, Athens, Greece; 11Genesis, Thessaloniki, Greece;  \n12Olympion General Clinic, Patras, Greece; 13Thessalia General Clinic, Larissa, Greece;  \n14 Breast Surgery, Larissa, Greece;  \n15 Hippokration General Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece;  \n16 Breast Surgery, Heraklion, Crete; 17Genesis Hospital, Thessaloniki, Greece;  \n18 Iaso General Clinic, Athens, Greece; 19 University General Hospital of Alexandroupolis, Alexandroupolis, Greece; 20 Department of Medical Oncology, Aristotle University of Thessaloniki, Papageorgiou Hospital, Thessaloniki, Greece; 21 Department of Medical Oncology, University General Hospital of Larissa, Larissa, Greece;  \n22 Department of Medical Oncology, University General Hospital of Alexandroupolis, Medical School, Democritus University of Thrace, Alexandroupolis, Greece;  \n23 Division of Oncology, Department of Medicine, University Hospital of Patras, Patras, Greece; 24 Metropolitan General Hospital, Athens, Greece  \nAbstract  \nBackground/Aim: In breast cancer, knowledge of the associations between clinicopathologic characteristics, genetic changes, and subtype-specific patterns is expanding. This study investigated how pathological and clinical variables affect the actionability of Next Generation Sequencing (NGS)-based tumor molecular data.  \ncontinued  \n✉Eirini Papadopoulou, Spaton 52 Ave, 15344 Gerakas, Athens, Greece. Tel: +30 2106032138, [e-mail: eirinipapad@genekor.com](e-mail: eirinipapad@genekor.com)  \nReceived April 18, 2026 | Revised June 9, 2026 | Accepted June 15, 2026  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n©2026 The Author(s) . Published by the International Institute of Anticancer Research.  \nMaterials and Methods: 227 breast cancer patients referred to Genekor’s laboratory for tumor molecular profile analysis were included in the study. Pathology records were used to assess critical clinicopathological features, including HER2, ER, PR, Ki67, grade, metastatic site, and age. A 1021-gene NGS-based multigene panel was utilized to assess tumor biology alongside tumor mutational burden (TMB) and microsatellite instability (MSI) .  \nResults: Comprehensive genomic profiling revealed that 95.6% of the patients harbored atleast one oncogenic or likely oncogenic alteration, highlighting the high diagnostic yield of NGS-based testing. Distinct subty","cbCaicQNoEs75TQL","https://ap.wps.com/l/cbCaicQNoEs75TQL","pdf",4034159,21,"English","# Abstract\n# Materials and Methods\n## Cohort and molecular profiling\n# Results\n## Actionable alterations by subtype\n## Impact of tumor-agnostic biomarkers\n# Conclusion\n# Keywords","[{\"question\":\"How many breast cancer patients were included in the study, and what molecular platform was used?\",\"answer\":\"The study included 227 breast cancer patients. A 1021-gene NGS-based multigene panel was used, together with tumor mutational burden (TMB) and microsatellite instability (MSI).\"},{\"question\":\"Which breast cancer subtypes showed distinct genomic alteration patterns?\",\"answer\":\"HR+/HER2- tumors were enriched for PIK3CA and ESR1 alterations, while triple-negative breast cancer (TNBC) was dominated by TP53 alterations.\"},{\"question\":\"What factors were associated with higher clinically actionable alterations?\",\"answer\":\"Actionable alterations were more frequent in HR+/HER2-tumors and increased on-label actionability up to 64.5% when tumor-agnostic biomarkers (TMB/MSI) were included. The presence of actionable alterations was significantly higher in metastatic tumors, and age was reported as the only independent predictor.\"}]","Tumor Mutational Landscape and Its Correlation With Histopathological Characteristics in Breast Cancer | PDF",1790123669,53,[148,152,156],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/e1869efd2ae90016838306215f5e759a.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/484fd5bf4dd72f49c4a30b6b875e9694.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/ca843782df77dd741070dabb72a6435c.webp",981,1308]